Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial

Abstract

Importance: Meta-analyses of randomized clinical trials have indicated that improved hypertension control reduces the risk for cognitive impairment and dementia. However, it is unclear to what extent pathways reflective of Alzheimer disease (AD) pathology are affected by hypertension control.

Objective: To evaluate the association of intensive blood pressure control on AD-related brain biomarkers.

Design, setting, and participants: This is a substudy of the Systolic Blood Pressure Intervention Trial (SPRINT MIND), a multicenter randomized clinical trial that compared the efficacy of 2 different blood pressure-lowering strategies. Potential participants (n = 1267) 50 years or older with hypertension and without a history of diabetes or stroke were approached for a brain magnetic resonance imaging (MRI) study. Of these, 205 participants were deemed ineligible and 269 did not agree to participate; 673 and 454 participants completed brain MRI at baseline and at 4-year follow-up, respectively; the final follow-up date was July 1, 2016. Analysis began September 2019 and ended November 2020.

Interventions: Participants were randomized to either a systolic blood pressure goal of less than 120 mm Hg (intensive treatment: n = 356) or less than 140 mm Hg (standard treatment: n = 317).

Main outcomes and measures: Changes in hippocampal volume, measures of AD regional atrophy, posterior cingulate cerebral blood flow, and mean fractional anisotropy in the cingulum bundle.

Results: Among 673 recruited patients who had baseline MRI (mean [SD] age, 67.3 [8.2] years; 271 women [40.3%]), 454 completed the follow-up MRI at a median (interquartile range) of 3.98 (3.7-4.1) years after randomization. In the intensive treatment group, mean hippocampal volume decreased from 7.45 cm3 to 7.39 cm3 (difference, -0.06 cm3; 95% CI, -0.08 to -0.04) vs a decrease from 7.48 cm3 to 7.46 cm3 (difference, -0.02 cm3; 95% CI, -0.05 to -0.003) in the standard treatment group (between-group difference in change, -0.033 cm3; 95% CI, -0.062 to -0.003; P = .03). There were no significant treatment group differences for measures of AD regional atrophy, cerebral blood flow, or mean fractional anisotropy.

Conclusions and relevance: Intensive treatment was associated with a small but statistically significant greater decrease in hippocampal volume compared with standard treatment, consistent with the observation that intensive treatment is associated with greater decreases in total brain volume. However, intensive treatment was not associated with changes in any of the other MRI biomarkers of AD compared with standard treatment.

Trial registration: ClinicalTrials.gov Identifier: NCT01206062.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Nasrallah reports grants from the National Institutes of Health (NIH) during the conduct of the study and personal fees from Biogen outside the submitted work. Dr Gaussoin reports grants from NIH and Alzheimer’s Association during the conduct of the study. Dr Erus reports grants from NIH for processing of magnetic resonance imaging data during the conduct of the study. Dr Wright reports royalties from UpToDate outside the submitted work. Dr Wolk reports grants from Biogen, Merck, and Eli Lilly and Company and personal fees from Functional Neuromodulation DSMB and Neuronix Consultation outside the submitted work. Dr Davatzikos reports grants from NIH during the conduct of the study. Dr Williamson reports grants from NIH during the conduct of the study. Dr Pajewski reports grants from NIH and Alzheimer’s Association during the conduct of the study. Dr Bryan reports grants from NIH during the conduct of the study; nonfinancial support from Galileo CDS outside the submitted work; and has a patent licensed to Galileo CDS. No other disclosures were reported.

Figures

Figure 1.. Eligibility, Randomization, and Follow-up For Participants in the Magnetic Resonance Imaging (MRI) Substudy

The total randomization number indicates the number of participants in the SPRINT MIND substudy who were within range of a study magnetic resonance imaging scanner.

Figure 2.. Longitudinal Change in Alzheimer Disease Magnetic Resonance Imaging Biomarkers by Age and Treatment Group

Bold lines represent age-specific change for each measurement estimated from a treatment group specific linear mixed model, with associated 95% CIs. Gray lines represent individual participant trajectories. ROIs indicate regions of interest; SPARE-AD, spatial pattern for recognition of Alzheimer disease.